SCHEMBL30008166

SCHEMBL30008166

COc1cc(C(=O)c2cc3c(ccc4ccccc43)[nH]2)ccc1N

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.52
LMNA P02545 2/20 0.52
KDM4E B2RXH2 1/20 0.52
HSD17B10 Q99714 1/20 0.52
FLT3 P36888 4/20 0.51
MEN1 O00255 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
TSHR P16473 1/20 0.44
KMT2A Q03164 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
PDGFRB P09619 4/20 0.43
PDGFRA P16234 4/20 0.43
TUBB4A P04350 1/20 0.41
TUBB P07437 1/20 0.41
TUBA3C P0DPH7 1/20 0.41
TUBA1B P68363 1/20 0.41
TUBA4A P68366 1/20 0.41
TUBB4B P68371 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2303556 1.00 ALDH1A1 (0.52) ALDH1A1LMNAKDM4EHSD17B10FLT3
SCHEMBL2302717 0.87 KDM4E (0.53) ALDH1A1LMNAKDM4EHSD17B10FLT3
SCHEMBL2301216 0.87 FLT3 (0.52) FLT3MEN1CYP1A2CYP3A4CYP2C9
SCHEMBL30008168 0.87 FLT3 (0.52) FLT3MEN1CYP1A2CYP3A4CYP2C9
SCHEMBL29402584 0.86 FLT3 (0.44) ALDH1A1LMNAKDM4EFLT3MEN1
SCHEMBL2300481 0.86 FLT3 (0.44) ALDH1A1LMNAKDM4EFLT3MEN1
SCHEMBL29402427 0.84 FLT3 (0.43) ALDH1A1LMNAFLT3TUBB4ATUBB
SCHEMBL2299223 0.84 FLT3 (0.43) ALDH1A1LMNAFLT3TUBB4ATUBB
SCHEMBL29402574 0.82 ALDH1A1 (0.56) ALDH1A1LMNAKDM4EHSD17B10FLT3
SCHEMBL2301360 0.82 ALDH1A1 (0.56) ALDH1A1LMNAKDM4EHSD17B10FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4340897-A1 METHODS AND COMPOSITIONS FOR TREATING PANCREATIC AND HEPATIC DISEASE METANOIA BIO INC. (US) 2024-03-27 EP disclosed
EP-4340835-A1 METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE METANOIA BIO INC. (US) 2024-03-27 EP disclosed
EP-4340896-A1 METHODS AND COMPOSITIONS FOR TREATING OCULAR NEOVASCULAR DISEASE METANOIA BIO INC. (US) 2024-03-27 EP disclosed
EP-4340836-A1 METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS METANOIA BIO INC. (US) 2024-03-27 EP disclosed
CN-116615241-A Methods and compositions for diabetes treatment and beta cell regeneration 加利福尼亚大学董事会 2023-08-18 CN disclosed
WO-2022245711-A1 METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS METANOIA BIO INC. (US) 2022-11-24 WO disclosed
WO-2022245698-A1 METHODS AND COMPOSITIONS FOR TREATING PANCREATIC AND HEPATIC DISEASE METANOIA BIO INC. (US) 2022-11-24 WO disclosed
WO-2022245697-A1 METHODS AND COMPOSITIONS FOR TREATING OCULAR NEOVASCULAR DISEASE METANOIA BIO INC. (US) 2022-11-24 WO disclosed
WO-2022245702-A1 METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE METANOIA BIO INC. (US) 2022-11-24 WO disclosed